Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial

Lan, CY; Zhao, J; Yang, F; Xiong, Y; Li, R; Huang, Y; Wang, J; Liu, C; Bi, XH; Jin, HH; Meng, J; Zhao, WH; Zhang, L; Wang, YF; Zheng, M; Huang, X

Huang, X (通讯作者)，Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, Guangzhou 510060, Peoples R China.;Huang, X (通讯作者)，Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.

CELL REPORTS MEDICINE, 2022; 3 (7):

Abstract

This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for plat-inum-resistant or-refractory ovarian cancer.......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索